Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Agamemnon Bakakos, Nikoletta Rovina, Stelios Loukides & Petros Bakakos. (2022) Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences. Expert Opinion on Biological Therapy 22:7, pages 855-870.
Read now
Read now
Maria Kallieri, Andriana I. Papaioannou, Evgenia Papathanasiou, Polyxeni Ntontsi, Spyridon Papiris & Stelios Loukides. (2017) Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgraduate Medicine 129:6, pages 598-604.
Read now
Read now
John O Warner. (2010) Omalizumab for childhood asthma. Expert Review of Respiratory Medicine 4:1, pages 5-7.
Read now
Read now
Dave P. Miller, Gladys Tom, Lawrence Rasouliyan & Bradley Chipps. (2009) Patient-Reported Outcomes among Omalizumab and Salmeterol/Fluticasone Combination Therapy Patients. Journal of Asthma 46:2, pages 179-185.
Read now
Read now
Garry M Walsh. (2008) Emerging drugs for asthma. Expert Opinion on Emerging Drugs 13:4, pages 643-653.
Read now
Read now
Andrew Menzies-Gow & Kian Fan Chung. (2008) Omalizumab for the treatment of severe allergic asthma. Expert Review of Clinical Immunology 4:5, pages 543-548.
Read now
Read now
Articles from other publishers (26)
Hale ATEŞ, Kurtuluş AKSU, Özlem ÖZDEDEOĞLU, Buket BAŞA AKDOĞAN, İlkay KOCA KALKAN, Gözde KÖYCÜ & Ferda ONER. (2021) Direct cost analysis for patients with severe asthma receiving omalizumab treatment. Journal of Health Sciences and Medicine 4:5, pages 735-740.
Crossref
Crossref
Jessica Purizaca-Bazán & José Antonio Ortega-Martell. (2020) Bloqueo de inmunoglobulina E en el asma grave. Revista Alergia México 67.
Crossref
Crossref
Chase S. Hall, James D. Quirk, Charles W. Goss, Daphne Lew, Jim Kozlowski, Robert P. Thomen, Jason C. Woods, Nicholas J. Tustison, John P. MuglerIIIIII, Lora Gallagher, Tammy Koch, Ken B. Schechtman, Iulian C. Ruset, F. William Hersman & Mario Castro. (2020)
Single-Session Bronchial Thermoplasty Guided by
129
Xe Magnetic Resonance Imaging. A Pilot Randomized Controlled Clinical Trial
. American Journal of Respiratory and Critical Care Medicine 202:4, pages 524-534.
Crossref
Crossref
Timm Volmer, Timo Effenberger, Christoph Trautner & Roland Buhl. (2018) Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. European Respiratory Journal 52:4, pages 1800703.
Crossref
Crossref
Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Zeynep Ferhan Özşeker, Papatya Bayrak Değirmenci , Sibel Naycı, Aykut Çilli, Füsun Erdenen, Cengiz Kırmaz, Dane Ediger, Arzu Didem Yalçın, Suna Büyüköztürk, Sami Öztürk, Mustafa Güleç, Sacide Rana Işık, Ali Fuat Kalyoncu, Özlem Göksel, Ömür Aydın, Yavuz Havlucu, İdilhan Baloğlu Ar & Ahmet Erdoğdu. (2018) Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial. International Archives of Allergy and Immunology 176:3-4, pages 225-233.
Crossref
Crossref
Mohit Bhutani, William H. Yang, Jacques Hébert, Frederica de Takacsy & Jean-Louis Stril. (2017) The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLOS ONE 12:8, pages e0183869.
Crossref
Crossref
Amira H. Allam, Amira A. Alkilani & Mysara M. Mogahed. (2017) Asthma related quality of life in western Saudi subpopulation and its correlation to level of asthma control. Egyptian Journal of Chest Diseases and Tuberculosis 66:1, pages 11-15.
Crossref
Crossref
Tianwen Lai, Shaobin Wang, Zhiwei Xu, Chao Zhang, Yun Zhao, Yue Hu, Chao Cao, Songmin Ying, Zhihua Chen, Wen Li, Bin Wu & Huahao Shen. (2015) Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports 5:1.
Crossref
Crossref
Sophia Tsabouri, Xanthippi Tseretopoulou, Konstantinos Priftis & Evangelia E. Ntzani. (2014) Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. The Journal of Allergy and Clinical Immunology: In Practice 2:3, pages 332-340.e1.
Crossref
Crossref
J. Ancochea, T. Chivato, P. Casan, C. Picado, L. Herráez & J. Casafont. (2014) Profile of patients treated with omalizumab in routine clinical practice in Spain. Allergologia et Immunopathologia 42:2, pages 102-108.
Crossref
Crossref
T. Vieira, J.F. de Oliveira & M. da Graça Castel-Branco. (2014) Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergologia et Immunopathologia 42:1, pages 3-10.
Crossref
Crossref
Garry M Walsh. (2013) An update on biologic-based therapy in asthma. Immunotherapy 5:11, pages 1255-1264.
Crossref
Crossref
Kate McKeage. (2013) Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma. Drugs 73:11, pages 1197-1212.
Crossref
Crossref
J. Sanchez, R. Ramirez, S. Diez, S. Sus, A. Echenique, M. Olivares & R. Cardona. (2012) Omalizumab beyond asthma. Allergologia et Immunopathologia 40:5, pages 306-315.
Crossref
Crossref
A. Dammak, C. Taillé, E. Marinho, B. Crestani, B. Crickx & V. Descamps. (2012) Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment for severe persistent allergic asthma: a case report. British Journal of Dermatology 166:6, pages 1375-1376.
Crossref
Crossref
Matthias Volkmar Kopp. (2011) Omalizumab: Anti-IgE Therapy in Allergy. Current Allergy and Asthma Reports 11:2, pages 101-106.
Crossref
Crossref
Smita PakhaleSunita MulpuruMatthew Boyd. (2011) Optimal Management of Severe/Refractory Asthma. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 5, pages CCRPM.S5535.
Crossref
Crossref
M. Massanari, S.T. Holgate, W.W. Busse, P. Jimenez, F. Kianifard & R. Zeldin. (2010) Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respiratory Medicine 104:2, pages 188-196.
Crossref
Crossref
Bob Lanier, Tracy Bridges, Marek Kulus, Angel Fowler Taylor, Indrias Berhane & Carlos Fernandez Vidaurre. (2009) Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. Journal of Allergy and Clinical Immunology 124:6, pages 1210-1216.
Crossref
Crossref
B. E. van Ewijk, A. L. M. Boehmer, H. J. L. Brackel, E. J. Duiverman, E. E. M. van Essen-Zandvliet, E. J. van de Griendt, C. A. C. Hugen, A. M. Landstra & F. G. A. Versteegh. (2009) Therapieresistent astma: behandelopties. Tijdschrift voor Kindergeneeskunde 77:6, pages 274-280.
Crossref
Crossref
Adalberto Pacheco-Galván, Miguel Hinojosa-Macías, Beatriz Hurtado-Barbudo, Jesús González-Cervera & Antonio Sueiro-Bendito. (2009) Control del asma y de la calidad de vida en pacientes asmáticos alérgicos graves con tratamiento anti-IgE (omalizumab). Medicina Clínica 133:12, pages 460-463.
Crossref
Crossref
Aidan A. Long, James E. Fish, Abdelkader Rahmaoui, Mary K. Miller, Mary S. Bradley, Hassan N. Taki, Anthony N. Demeo, Stephen A. Tilles & Stanley J. Szefler. (2009) Baseline characteristics of patients enrolled in EXCELS: a cohort study. Annals of Allergy, Asthma & Immunology 103:3, pages 212-219.
Crossref
Crossref
Christopher WT Miller, Narayanaswamy Krishnaswamy, Chambless Johnston & Guha Krishnaswamy. (2008) Severe asthma and the omalizumab option. Clinical and Molecular Allergy 6:1.
Crossref
Crossref
Jenny M. CampbellM.D.M.D., Jonathan D. WoffordM.P.H.M.P.H. & Alan P. KnutsenM.D.M.D.. (2008) Omalizumab Treatment in Children 6 to 18 Years Old with Severe Asthma at a Children’s Medical Center. Pediatric Asthma, Allergy & Immunology 21:3, pages 129-136.
Crossref
Crossref
Paul P Belliveau & Monina R Lahoz. (2007) Treating Allergic Asthma with Omalizumab. Disease Management & Health Outcomes 15:3, pages 165-179.
Crossref
Crossref
. (2013) Add-on omalizumab improves QOL in severe allergic asthma. PharmacoEconomics & Outcomes News 518:1, pages 9-9.
Crossref
Crossref